首页> 外文OA文献 >Affinity of (+/-)-pindolol, (-)-penbutolol, and (-)-tertatolol for pre- and postsynaptic serotonin 5-HT(1A) receptors in human and rat brain.
【2h】

Affinity of (+/-)-pindolol, (-)-penbutolol, and (-)-tertatolol for pre- and postsynaptic serotonin 5-HT(1A) receptors in human and rat brain.

机译:(+/-)-哌多洛尔,(-)-苯丁酚和(-)-叔他洛尔对人和大鼠大脑中突触前和血清后5-羟色胺5-HT(1A)受体的亲和力。

摘要

There is considerable interest in the use of drugs that selectively block presynaptic (somatodendritic) serotonin 5-HT(1A) receptors for the adjunctive treatment of major depressive disorder. The 5-HT(1A)/beta-adrenoceptor ligands (+/-)-pindolol, (-)-tertatolol, and (-)-penbutolol are currently under clinical investigation, and knowledge of their affinity at different populations of central 5-HT(1A) receptors is needed. Here we have determined the affinity of these drugs for presynaptic and postsynaptic 5-HT(1A) receptors in postmortem human and rat brain using receptor autoradiography and the selective 5-HT(1A) radioligand [(3)H]WAY-100635. The binding of [(3)H]WAY-100635 was specific and saturable and showed high affinity in the rat dorsal raphe nucleus and hippocampus (K(D) = 1.5-1.7 nM). In competition studies, the three compounds had nanomolar affinity and produced monophasic displacement of [(3)H]WAY-100635 binding in all regions of both species. (-)-Penbutolol and (-)-tertatolol had similar affinity for pre-and postsynaptic 5-HT(1A) receptors in both rat and human brain. However, in the human, but not the rat, the affinity of (+/-)-pindolol in dorsal raphe nucleus (K(i) = 8.9 +/- 1. 1 nM) was slightly but significantly higher than that in hippocampus (K(i) = 14.4 +/- 1.5 nM in CA1). In summary, our data show that (+/-)-pindolol, (-)-tertatolol, and (-)-penbutolol are all high-affinity ligands at native human and rat 5-HT(1A) receptors. (-)-Penbutolol and (-)-tertatolol do not discriminate between the pre- and postsynaptic 5-HT(1A) sites tested in either species, but (+/-)-pindolol showed a slightly higher affinity for the presynaptic site in human brain. Further work is needed to establish whether the latter difference is clinically relevant.
机译:使用药物选择性阻断突触前(体树突状)5-羟色胺5-HT(1A)受体用于重大抑郁症的辅助治疗。 5-HT(1A)/β-肾上腺素受体配体(+/-)-哌多洛尔,(-)-叔他洛尔和(-)-苯丁洛尔目前正在临床研究中,并且了解它们在中枢5位不同人群中的亲和力HT(1A)受体是必需的。在这里,我们使用受体放射自显影和选择性5-HT(1A)放射性配体[(3)H] WAY-100635,确定了这些药物对死后人类和大鼠大脑中突触前和突触后5-HT(1A)受体的亲和力。 [(3)H] WAY-100635的结合是特异性和可饱和的,并且在大鼠背沟纹核和海马中显示出高亲和力(K(D)= 1.5-1.7 nM)。在竞争研究中,这三种化合物具有纳摩尔摩尔亲和力,并且在两个物种的所有区域中均产生[(3)H] WAY-100635结合的单相置换。 (-)-Pentbutolol和(-)-teratatolol对大鼠和人脑中突触前和突触后5-HT(1A)受体具有相似的亲和力。然而,在人类而非大鼠中,(+/-)-品多洛尔在背缝核中的亲和力(K(i)= 8.9 +/-1。1nM)略高于海马(但)。在CA1中,K(i)= 14.4 +/- 1.5 nM。总而言之,我们的数据显示,(+/-)-潘多洛尔,(-)-叔他洛尔和(-)-苯丁酚都为天然人和大鼠5-HT(1A)受体的高亲和力配体。 (-)-苯丁洛尔和(-)-叔他洛尔在两种物种中均未区分突触前和突触后5-HT(1A)位点,但(+/-)-哌多洛尔对突触前位点的亲和力略高人脑。需要进一步的工作来确定后一种差异是否在临床上相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号